The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Setmelanotide looks approvable, but patients were stratified for inclusion in some measures.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.